Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning
Carregando...
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.74, article ID e835, 8p, 2019
Resumo
The efficacy and toxicity of radionuclide therapy are believed to be directly related to the radiation doses received by target tissues; however, nuclear medicine therapy continues to be based primarily on the administration of empirical activities to patients and less frequently on the use of internal dosimetry for individual therapeutic planning. This review aimed to critically describe the techniques and clinical evidence of dosimetry as a tool for therapeutic planning and the main limitations to its implementation in clinical practice. The present article is a nonsystematic review of voxel-based dosimetry. Clinical evidence pointing to a correlation between the radiation dose and therapeutic response in various diseases, such as thyroid carcinoma, neuroendocrine tumors and prostate cancer, is reviewed. Its limitations include technical aspects related to image acquisition and processing and the lack of randomized clinical trials demonstrating the impact of dosimetry on patient therapy. A more widespread use of dosimetry in therapeutic planning involves the development of user-friendly dosimetric protocols and confirmation that dose estimation implies good efficacy and low treatment-related toxicity.
Palavras-chave
Nuclear Medicine, Radionuclide Imaging, In vivo Dosimetry
Referências
- Bardies M, 2011, Q J NUCL MED MOL IM, V55, P5
- BENUA RS, 1962, AMER J ROENTGENOL RA, V87, P171
- Chalkia MT, 2015, AUSTRALAS PHYS ENG S, V38, P7, DOI 10.1007/s13246-014-0312-7
- Chiesa C, 2011, Q J NUCL MED MOL IM, V55, P168
- Cives M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0567-8
- Deandreis D, 2017, J NUCL MED, V58, P717, DOI 10.2967/jnumed.116.179606
- Dewaraja Y, 2012, J NUCL MED, V53, DOI 10.2967/jnumed.111.100123
- Dewaraja YK, 2013, J NUCL MED, V54, P2182, DOI 10.2967/jnumed.113.122390
- Flux GD, 2010, EUR J NUCL MED MOL I, V37, P270, DOI 10.1007/s00259-009-1261-3
- Garin E, 2016, EUR J NUCL MED MOL I, V43, P559, DOI 10.1007/s00259-015-3157-8
- Garin E, 2015, J NUCL MED, V56, P339, DOI 10.2967/jnumed.114.145177
- Gaze MN, 2013, Q J NUCL MED MOL IM, V57, P66
- Hanscheid H, 2018, J NUCL MED, V59, P75, DOI 10.2967/jnumed.117.193706
- Heikkonen J, 2016, ACTA ONCOL, V55, P1069, DOI 10.1080/0284186X.2016.1182642
- Hendlisz A, 2010, J CLIN ONCOL, V28, P3687, DOI 10.1200/JCO.2010.28.5643
- Higashi T, 2011, J NUCL MED, V52, P683, DOI 10.2967/jnumed.110.081059
- Jentzen W, 2008, EUR J NUCL MED MOL I, V35, P611, DOI 10.1007/s00259-007-0554-7
- Jentzen W, 2014, J NUCL MED, V55, P1759, DOI 10.2967/jnumed.114.144089
- Kairemo K, 2015, DIAGNOSTICS, V5, P358, DOI 10.3390/diagnostics5030358
- Klubo-Gwiezdzinska J, 2011, J CLIN ENDOCR METAB, V96, P3217, DOI 10.1210/jc.2011-0494
- Kulkarni K, 2006, THYROID, V16, P1019, DOI 10.1089/thy.2006.16.1019
- Kumar C, 2016, INT J RADIAT BIOL, V92, P173, DOI 10.3109/09553002.2016.1144944
- Lassmann M, 2013, EUR J NUCL MED MOL I, V40, P207, DOI 10.1007/s00259-012-2265-y
- Mattsson S, 2015, RADIAT PROT DOSIM, V165, P416, DOI 10.1093/rpd/ncv061
- MAXON HR, 1992, J NUCL MED, V33, P1132
- MAXON HR, 1983, NEW ENGL J MED, V309, P937, DOI 10.1056/NEJM198310203091601
- Mazzaferri E L, 2000, Endocr Pract, V6, P469
- Minguez P, 2015, MED PHYS, V42, P3969, DOI 10.1118/1.4921807
- OCONNELL MEA, 1993, RADIOTHER ONCOL, V28, P16, DOI 10.1016/0167-8140(93)90180-G
- Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
- Pauwels S, 2005, J NUCL MED, V46, p92S
- Pereira JM, 2010, HEALTH PHYS, V99, P688, DOI 10.1097/HP.0b013e3181e28cdb
- Prideaux AR, 2007, J NUCL MED, V48, P1008, DOI 10.2967/jnumed.106.038000
- Salem R, 2016, GASTROENTEROLOGY, V151, P1155, DOI 10.1053/j.gastro.2016.08.029
- Sawka AM, 2018, THYROID, V28, P692, DOI 10.1089/thy.2018.0070
- SEIDLIN SM, 1946, JAMA-J AM MED ASSOC, V132, P838, DOI 10.1001/jama.1946.02870490016004
- Sgouros G, 2004, J NUCL MED, V45, P1366
- Sgouros G, 2011, EUR J NUCL MED MOL I, V38, P41, DOI 10.1007/s00259-011-1769-1
- Shen S, 2002, J NUCL MED, V43, P1245
- Smits MLJ, 2015, CARDIOVASC INTER RAD, V38, P261, DOI 10.1007/s00270-014-1042-7
- Stabin M, 2006, PHYS MED BIOL, V51, pR187, DOI 10.1088/0031-9155/51/13/R12
- Sudbrock F, 2010, EUR J NUCL MED MOL I, V37, P1279, DOI 10.1007/s00259-010-1391-7
- Tong AKT, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150943
- Trieu M, 2016, PEDIATR BLOOD CANCER, V63, P436, DOI 10.1002/pbc.25816
- Tung JN, 2018, ONCOTARGET, V9, P4637, DOI 10.18632/oncotarget.23161
- Willegaignon J, 2016, ALASBIMN J
- Willegaignon J, 2016, NUCL MED COMMUN, V37, P473, DOI 10.1097/MNM.0000000000000465
- Willegaignon J, 2012, RADIAT PROT DOSIM, V149, P138, DOI 10.1093/rpd/ncr214
- Wilson JS, 2014, EUR J CANCER, V50, P801, DOI 10.1016/j.ejca.2013.11.016